Search Bar & Filters
Found 1703 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of personalized, dynamic titanium prostheses made with 3D printing to reconstruct the chest wall after tumor removal or severe trauma. This study addresses the challenges of traditional rigid reconstruction methods that can cause pain or breathing difficulties by testing implants designed to mimic natural rib movement, potentially improving function and comfort. The study is a multicenter, ambispective registry collecting both retrospective and prospective data across major Spanish hospitals. The treatment involves creating a custom 3D-printed titanium prosthesis based on preoperative CT scans, manufactured using titanium alloy powder. During surgery, the prosthesis is implanted and anchored to the ribs or sternum to restore chest wall integrity while preserving natural dynamics. The study includes retrospective cases and prospective enrollment over 24 months, with follow-up evaluations at discharge, 1 month, 6 months, and 12 months post-surgery. Participants will undergo assessments including pulmonary function tests, pain scales, imaging like X-rays and CT scans, and quality of life questionnaires. Data is securely stored and anonymized in a centralized database compliant with European data protection laws. The primary outcomes measure changes in lung function parameters over one year. Participants can withdraw at any time, and the study aims to improve prosthesis design and surgical practices through comprehensive monitoring and analysis.
Actively Recruiting
Researchers are evaluating CGT9486 bezuclastinib in an open-label Phase 2 study for patients with Advanced Systemic Mastocytosis AdvSM, including Aggressive Systemic Mastocytosis ASM, Systemic Mastocytosis with an Associated Hematologic Neoplasm SM-AHN, and Mast Cell Leukemia MCL. The study aims to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of bezuclastinib as a single agent in these conditions. Participants receive bezuclastinib tablets orally, taken continuously in 28-day cycles. The study has two parts Part I focuses on identifying clinically active and tolerable doses of bezuclastinib, while Part II determines the drugs efficacy by measuring the modified IWG Objective Response Rate ORR and confirming the exposure-response relationship. Treatment and evaluation continue for up to 18 months. During the study, participants undergo assessments including laboratory tests, imaging to measure spleen and liver volume, and evaluation of mutation allele burden, serum tryptase, and histopathologic changes in blood and bone marrow. Safety is monitored through adverse event reporting. The study measures duration and time to response, progression-free survival, and overall survival. Participants are involved in regular monitoring throughout the treatment period extending up to 18 months.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.
Actively Recruiting
Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.
Actively Recruiting
Researchers are evaluating the AGIL Barcelona program to help frail older adults improve their physical abilities and delay disability. This study focuses on adapting and expanding the program across different community health centers in Barcelona. It aims to measure improvements in physical performance using a simple test SPPB and assess how well the program can be implemented in various neighborhoods. The program includes up to 10 weekly group exercise sessions led by a physiotherapist, emphasizing strength, balance, flexibility, and endurance. Participants receive personalized exercises supported by easy-to-understand materials. The program also offers advice on healthy habits like the Mediterranean diet, sleep improvement, and managing swallowing or memory issues. Medication reviews are conducted to ensure safe and appropriate treatments, and support is provided to connect participants with local activities to reduce social isolation. Participants will be involved in assessments of their physical performance, quality of life, cognitive function, social engagement, diet adherence, medication use, and any adverse events at the start, three months, and six months. The study uses a stepped approach to introduce the program at different sites gradually. Researchers will also gather qualitative feedback on participants experiences and program implementation. The total participation duration includes baseline and follow-up visits over six months.
Actively Recruiting
Randomized Phase II Study of 177Lu-DOTATATE Radioligand Therapy for Adults with Recurrent Meningioma
Researchers are investigating new treatment options for meningiomas that continue to grow despite local therapies like surgery or radiotherapy. This trial focuses on evaluating a precision medicine approach that combines PET-based imaging to select patients with tumors expressing somatostatin receptors and a targeted radioligand therapy called 177Lu-DOTATATE. This is the first randomized clinical trial studying this therapy in patients with meningiomas that have not responded to other treatments. Participants will be randomly assigned to one of two groups. One group receives 177Lu-DOTATATE through intravenous infusions every four weeks for a total of four cycles. The other group receives local standard care, which may include treatments like hydroxyurea, bevacizumab, sunitinib, octreotide, everolimus, or observation with supportive care, based on the investigators choice. This study is designed to compare the effects of 177Lu-DOTATATE against various standard treatments in this patient population. During the study, participants will undergo regular MRI scans to measure tumor size and progression. Researchers will also assess overall survival, neurological function, quality of life, and treatment side effects over a period extending up to two years after enrollment. Monitoring includes imaging, laboratory tests, and health questionnaires to evaluate how the disease and treatments affect participants over time.
Actively Recruiting
Healthy Volunteer
This research aims to assess the current work situation of anaesthesiology services in Spain, 20 years after the first comprehensive record called ANESCAT 2003. It evaluates whether the increase in healthcare activity matches the growth in resources allocated to the specialty and provides objective data for future planning and demands. The study focuses on collecting data on anaesthesia activities across several areas, including surgical procedures, intensive care units, chronic pain units, and delivery rooms. This data is gathered through various questionnaires covering a 14-day activity period over the course of one year. Participants will be involved by having their anaesthesia work activity recorded during this 14-day period. Researchers will measure the extent of anaesthesia services in different clinical settings and evaluate staff activity levels, as well as the role of anaesthesiology in managing polytrauma patients and cardiorespiratory arrest. The study spans one year to capture comprehensive activity data.
Actively Recruiting
Kienbocks disease, a condition involving ischemic necrosis of the lunate bone, has several surgical treatments depending on the disease stage and anatomical risk factors. This research focuses on stages II and III of the disease. Various surgeries aim to unload the lunate bone, restore its blood supply, or replace damaged parts, with most options working to maintain wrist structure, prevent disease progression, and reduce pain. This study evaluates the use of 3D printing models and personalized guides to plan different types of radial osteotomies tailored to patients anatomical features. These osteotomies include radial shortening, closed wedge, and dorsolateral biplane closing osteotomies, chosen based on factors like cubitus minus and radial inclination angle. The procedures involve osteosynthesis with a plate on the distal radius to decompress and protect the lunate bone. Participants will undergo clinical and radiological evaluations before and after surgery, including assessments of wrist function, pain, grip strength, and range of motion. Radiographic measurements such as Lichtman classification, carpal height ratio, and various wrist angles will be monitored over 22 months. These evaluations aim to track changes related to the surgical planning aided by 3D models, with ongoing follow-up to assess outcomes and recovery.
Actively Recruiting
Healthy Volunteer
Researchers are working to create and use a comprehensive database focused on intracranial aneurysms IA. This project collects and studies clinical history, imaging data, biological samples, and other information to understand factors linked to the formation and rupture of aneurysms. They aim to identify genetic, environmental, and anatomical markers, as well as evaluate outcomes from different treatment strategies and improve patient care protocols. Participants include patients with diagnosed aneurysms, both ruptured and unruptured, family members of affected individuals, and healthy volunteers. Data collected involves detailed clinical records, imaging scans like MRI angiography and CT angiography, and various biological samples such as blood, cerebrospinal fluid, saliva, and stool. Consent covers access to medical records, use of biological samples, and potential future research uses including genetic analyses. During the study, participants provide health and lifestyle information, imaging data, and biological samples. Researchers will monitor multiple long-term outcomes including disease progression, life expectancy, quality of life, neurological and cognitive status, and treatment effects over periods up to 20 years. Data confidentiality is maintained, and participants can withdraw at any time without affecting their medical care. The study aims to validate disease models and support advances in aneurysm management and research.
Actively Recruiting
Researchers are conducting an open-label, multi-site, multi-cohort phase 12 trial to evaluate ODM-212 combined with other anti-cancer therapies in adults with advanced solid tumors such as mesothelioma, pancreatic cancer, and advanced non-small cell lung cancer NSCLC. The study aims to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and effectiveness of these combinations. The trial is divided into two parts dose escalation and dose expansionoptimization. Participants receive ODM-212 tablets alongside specified anti-cancer therapies depending on their cancer type. These include ipilimumab and nivolumab for mesothelioma, gemcitabine with nab-paclitaxel for pancreatic cancer, and sotorasib for NSCLC with a KRAS G12C mutation. Each drug has specific dosing schedules, such as intravenous infusions every 3 to 6 weeks or daily oral dosing in 21-day cycles. Participants will be monitored throughout the study for dose-limiting toxicities and adverse events over an average of 2 years. They will record daily adherence to oral medications and undergo evaluations including tumor biopsies and response assessments. The study involves regular visits for treatment administration and safety monitoring, with eligibility requiring good performance status and the ability to take oral medication.
1-10 of 1,703
1